Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced on Wednesday that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its chikungunya vaccine candidate.

Bavarian Nordic's single-dose vaccine is designed to prevent chikungunya infection in people aged 12 and older.

The application benefits from accelerated assessment granted by the EMA in February 2024, potentially leading to European Commission approval in the first half of 2025.

The chikungunya vaccine demonstrated strong immune response in two Phase 3 trials with over 3,600 participants and was well-tolerated with mostly mild or moderate side effects.